Approval · Notice of Compliance 27066 · 2021
LUPRON: Notice of Compliance 27066
Issued November 19, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27066
- Date
- November 19, 2021
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUPRON | Not yet assigned | — |
| LUPRON DEPOT | Not yet assigned | — |
Medicinal ingredients
- LEUPROLIDE ACETATE 5 MG per ML
- LEUPROLIDE ACETATE 3.75 MG per SYR
- LEUPROLIDE ACETATE 7.5 MG per SYR
- LEUPROLIDE ACETATE 22.5 MG per SYR
- LEUPROLIDE ACETATE 30 MG per SYR
- LEUPROLIDE ACETATE 11.25 MG per SYR